Intensity Therapeutics (INTS) Income Statement (2022 - 2026)
Income Statement report data from Jun 30, 2022 to Mar 31, 2026 for Intensity Therapeutics (INTS).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||
Research And Development | 1.20M (-20.00%) | 1.50M (-3.23%) | 1.55M (+0.65%) | 1.54M (-29.68%) | 2.19M (+11.17%) | 1.97M (-8.37%) | 2.15M (-39.61%) | 3.56M (+26.24%) | 2.82M (+108.89%) | 1.35M (+56.98%) | 860K (+11.69%) | 770K (-35.83%) | 1.20M (+3.45%) | 1.16M (-16.55%) | 1.39M |
Selling General And Administrative | 1.33M (-18.90%) | 1.64M (+38.98%) | 1.18M (+1.72%) | 1.16M (-4.13%) | 1.21M (-2.42%) | 1.24M (-12.68%) | 1.42M (-5.96%) | 1.51M (-21.76%) | 1.93M (+69.30%) | 1.14M (+216.67%) | 360K (-25.00%) | 480K (-33.33%) | 720K (+18.03%) | 610K (+12.96%) | 540K |
Operating Expenses | 2.53M (-19.43%) | 3.14M (+15.02%) | 2.73M (+0.74%) | 2.71M (-20.06%) | 3.39M (+5.94%) | 3.20M (-10.36%) | 3.57M (-29.59%) | 5.07M (+6.96%) | 4.74M (+90.36%) | 2.49M (+104.10%) | 1.22M (-2.40%) | 1.25M (-34.90%) | 1.92M (+8.47%) | 1.77M (-8.29%) | 1.93M |
Operating Income | |||||||||||||||
Operating Income | -2.53M (-19.43%) | -3.14M (+15.02%) | -2.73M (+1.11%) | -2.70M (-20.35%) | -3.39M (+5.94%) | -3.20M (-10.36%) | -3.57M (-29.59%) | -5.07M (+6.96%) | -4.74M (+90.36%) | -2.49M (+104.10%) | -1.22M (-2.40%) | -1.25M (-34.90%) | -1.92M (+8.47%) | -1.77M (-8.29%) | -1.93M |
Ebit | -2.53M (-19.43%) | -3.14M (+15.02%) | -2.73M (+1.11%) | -2.70M (-20.35%) | -3.39M (+5.94%) | -3.20M (-10.36%) | -3.57M (-29.59%) | -5.07M (+6.96%) | -4.74M (+90.36%) | -2.49M (+104.10%) | -1.22M (-2.40%) | -1.25M (-34.90%) | -1.92M (+8.47%) | -1.77M (-8.29%) | -1.93M |
EBITDA | -2.43M (-20.33%) | -3.05M (+14.23%) | -2.67M (+5.12%) | -2.54M (-24.18%) | -3.35M (+5.35%) | -3.18M (-9.40%) | -3.51M (-29.38%) | -4.97M (+8.04%) | -4.60M (+97.42%) | -2.33M (-33.05%) | -3.48M (+178.40%) | -1.25M (-34.55%) | -1.91M (+8.52%) | -1.76M (-7.85%) | -1.91M |
Other Income / Expenses | |||||||||||||||
Interest Income | 90K (0.00%) | 90K (+50.00%) | 60K (+200.00%) | 20K (0.00%) | 20K (-33.33%) | 30K (-40.00%) | 50K (-50.00%) | 100K (-28.57%) | 140K (-6.67%) | 150K | - | - | - | - | - |
Interest Expense | - | - | - | - | - | - | - | - | - | - | 220K (+175.00%) | 80K (+100.00%) | 40K (+100.00%) | 20K (+100.00%) | 10K |
Net Interest Income | 90K (0.00%) | 90K (+50.00%) | 60K (+200.00%) | 20K (0.00%) | 20K (-33.33%) | 30K (-40.00%) | 50K (-50.00%) | 100K (-28.57%) | 140K (-6.67%) | 150K | -220.00K (+175.00%) | -80.00K (+100.00%) | -40.00K (+300.00%) | -10.00K (0.00%) | -10.00K |
Other Non Operating Income | - | 190K | - | 150K (+400.00%) | 30K | - | 10K | - | - | 10K | - | - | - | - | - |
Net Income | |||||||||||||||
Net Income From Continuing Operations | -2.43M (-20.33%) | -3.05M (+14.23%) | -2.67M (+5.12%) | -2.54M (-24.18%) | -3.35M (+5.35%) | -3.18M (-9.40%) | -3.51M (-29.38%) | -4.97M (+8.04%) | -4.60M (+97.42%) | -2.33M (-37.03%) | -3.70M (+176.12%) | -1.34M (-31.28%) | -1.95M (+10.17%) | -1.77M (-8.29%) | -1.93M |
Net Income | -2.43M (-20.33%) | -3.05M (+14.23%) | -2.67M (+5.12%) | -2.54M (-24.18%) | -3.35M (+5.35%) | -3.18M (-9.40%) | -3.51M (-29.38%) | -4.97M (+8.04%) | -4.60M (+97.42%) | -2.33M (-37.03%) | -3.70M (+176.12%) | -1.34M (-31.28%) | -1.95M (+10.17%) | -1.77M (-8.29%) | -1.93M |